< Back to previous page
Organisation
Digestive Oncology
Division
Main organisation:Department of Oncology
Lifecycle:1 Aug 2022 → Today
Organisation profile:
Digestive Oncology
Keywords:oncology
Disciplines:Oncology
Current researchers
1 - 10 of 12 results
- Sabine Tejpar (Responsible)
- Sarah Cappuyns (Member)
- Jeroen Dekervel (Member)
- Frederik Peeters (Member)
- Ting Pu (Member)
- Sabine Tejpar (Member)
- Baki Topal (Member)
- Eric Van Cutsem (Member)
- Fausto Velez Bravo (Member)
- Sara Verbandt (Member)
Projects
1 - 10 of 55
- Querying and exploiting the spatial colorectal tumor ecosystem for novel biological, diagnostic and therapeutic insightsFrom23 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The evolutionary landscape of colorectal cancer, from polyp to metastasisFrom25 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Multicenter validation trial of [18F]AlF-FAPI-74 for PET imaging of cancer-associated fibroblasts through fibroblast activation protein inhibitors (FAPI) in digestive tumorsFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimizing a high throughput TCR-epitope recognition tool to characterize microbiome specific TCR interactions in colorectal cancerFrom1 Oct 2023 → TodayFunding: BOF - doctoral mandates
- Non-genetic drivers of YAP activation in colorectal cancerFrom26 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Study the efficacy and mechanism of targeted TIM3 and VISTA in the treatment of gastroesophageal junction / gastric cancer patients with low immunogenicity and FLOT chemotherapy resistanceFrom14 Feb 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Using mucins as friends in colorectal cancer diagnostics and treatmentFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Infrastructure for Targeted ProteomicsFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 1033
- Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer(2022)
Authors: Eric Van Cutsem
- Different surgical strategies in the treatment of familial adenomatous polyposis: what's the role of the ileorectal anastomosis?(2011)
Authors: Albert Wolthuis, Eric Van Cutsem
Pages: 435 - 437 - Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation(2011)
Authors: Albert Wolthuis, Freddy Penninckx, Karin Haustermans, Nadine Ectors, Eric Van Cutsem
Pages: 684 - 690 - The prognostic relevance of tumor hypoxia markers in resected carcinoma of the gallbladder(2011)
Authors: Evelyne Lerut, Nadine Ectors, Baki Topal
Pages: 80 - 86 - Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up(2009)
Authors: Eric Van Cutsem
Pages: 49 - 50 - Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs)(2020)
Authors: Eric Van Cutsem, Karin Haustermans
Pages: S420 - S421 - Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database(2022)
Authors: Eric Van Cutsem
Pages: 142 - 152 - Perioperative cancer cell dissemination and Systemic immunological changes in resectable Pancreatic Ductal Adenocarcinoma(2011)
Authors: Baki Topal, Tania Roskams
- Lynch syndrome (HNPCC)(2010)
Authors: Jozef Janssens, Sabine Tejpar
Pages: 808 - 817 - Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.(2023)
Authors: Eric Van Cutsem
Pages: 1655 - 1668